Merck : Phase 3 Study Of KEYTRUDA – Chemotherapy On Metastatic Esophageal Cancer Meets Main Goal

Merck & Co., Inc.(MRK) said that the pivotal Phase 3 KEYNOTE-590 trial evaluating the company’s anti-PD-1 therapy KEYTRUDA in combination with chemotherapy met its primary endpoints of overall survival or OS and progression-free survival or PFS for the first-line treatment of patients with locally advanced or metastatic esophageal cancer.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *